

Nimish Vakil

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4198989/nimish-vakil-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

141
papers

11,435
citations

44
h-index

106
g-index

155
ext. papers

12,873
ext. citations

5.2
avg, IF

6.17
L-index

#	Paper	IF	Citations
141	The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. <i>American Journal of Gastroenterology</i> , 2006 , 101, 1900-20; quiz 1943	0.7	2533
140	Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. <i>Gut</i> , 2007 , 56, 772-81	19.2	1326
139	A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer. <i>New England Journal of Medicine</i> , 1993 , 329, 1302-7	59.2	623
138	Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 30, 1030-8	6.1	349
137	Guidelines for the management of dyspepsia. <i>American Journal of Gastroenterology</i> , 2005 , 100, 2324-37	0.7	349
136	A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. <i>American Journal of Gastroenterology</i> , 2009 , 104, 1278-95; quiz 1296	0.7	306
135	Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. <i>Annals of Internal Medicine</i> , 2003 , 138, 176-86	8	277
134	Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. <i>New England Journal of Medicine</i> , 1999 , 341, 1106-11	59.2	277
133	ACG and CAG Clinical Guideline: Management of Dyspepsia. <i>American Journal of Gastroenterology</i> , 2017 , 112, 988-1013	0.7	259
132	A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. <i>American Journal of Gastroenterology</i> , 2001 , 96, 1791-6	0.7	241
131	Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. <i>Annals of Internal Medicine</i> , 2007 , 146, 556-63	8	218
130	Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. <i>American Journal of Gastroenterology</i> , 2009 , 104, 3069-79; quiz 1080	0.7	211
129	Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. <i>Gut</i> , 2010 , 59, 714-21	19.2	210
128	The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. <i>Gastroenterology</i> , 2004 , 127, 1329-37	13.3	181
127	Eradication therapy for Helicobacter pylori. <i>Gastroenterology</i> , 2007 , 133, 985-1001	13.3	179
126	Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. <i>BMJ, The</i> , 2013 , 347, f4587	5.9	178
125	Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. <i>Gastroenterology</i> , 2006 , 131, 390-401; quiz 659-60	13.3	166

124	High eradication rates of <i>Helicobacter pylori</i> with a new sequential treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2003 , 17, 719-26	6.1	161
123	Empiric quadruple vs. triple therapy for primary treatment of <i>Helicobacter pylori</i> infection: Systematic review and meta-analysis of efficacy and tolerability. <i>American Journal of Gastroenterology</i> , 2010 , 105, 65-73	0.7	149
122	Antimicrobial resistance incidence and risk factors among <i>Helicobacter pylori</i> -infected persons, United States. <i>Emerging Infectious Diseases</i> , 2004 , 10, 1088-94	10.2	144
121	Clinical effectiveness of laparoscopic fundoplication in a U.S. community. <i>American Journal of Medicine</i> , 2003 , 114, 1-5	2.4	137
120	Seven-day therapy for <i>Helicobacter pylori</i> in the United States. <i>Alimentary Pharmacology and Therapeutics</i> , 2004 , 20, 99-107	6.1	119
119	Can the clinical history distinguish between organic and functional dyspepsia?. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 1566-76	27.4	115
118	Human tissue responses to metal stents implanted in vivo for the palliation of malignant stenoses. <i>Gastrointestinal Endoscopy</i> , 1996 , 43, 596-602	5.2	96
117	BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. <i>American Journal of Gastroenterology</i> , 2015 , 110, 662-82; quiz 683	0.7	92
116	The stool antigen test for detection of <i>Helicobacter pylori</i> after eradication therapy. <i>Annals of Internal Medicine</i> , 2002 , 136, 280-7	8	88
115	Review article: <i>Helicobacter pylori</i> and reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003 , 17, 297-305	6.1	80
114	Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 1360-6	6.9	76
113	A prospective trial of self-expanding metal stents in the palliation of malignant esophageal obstruction after failure of primary curative therapy. <i>Gastrointestinal Endoscopy</i> , 1996 , 44, 283-6	5.2	71
112	Recurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal ulcer treated for <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2000 , 14, 45-51	6.1	70
111	Clarithromycin-resistant <i>Helicobacter pylori</i> in patients with duodenal ulcer in the United States. <i>American Journal of Gastroenterology</i> , 1998 , 93, 1432-5	0.7	69
110	Review article: how valuable are proton-pump inhibitors in establishing a diagnosis of gastro-oesophageal reflux disease?. <i>Alimentary Pharmacology and Therapeutics</i> , 2005 , 22 Suppl 1, 64-9	6.1	66
109	Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. <i>American Journal of Gastroenterology</i> , 2008 , 103, 1906-19	0.7	64
108	Review article: new pharmacological agents for the treatment of gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2004 , 19, 1041-9	6.1	55
107	A prospective trial of a new self-expanding plastic stent for malignant esophageal obstruction. <i>American Journal of Gastroenterology</i> , 2001 , 96, 1350-4	0.7	54

106	Upper GI malignancy, uncomplicated dyspepsia, and the age threshold for early endoscopy. <i>American Journal of Gastroenterology</i> , 2002 , 97, 600-3	0.7	54
105	Symptom overlap between postprandial distress and epigastric pain syndromes of the Rome III dyspepsia classification. <i>American Journal of Gastroenterology</i> , 2013 , 108, 767-74	0.7	53
104	Disease definition, clinical manifestations, epidemiology and natural history of GERD. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2010 , 24, 759-64	2.5	53
103	Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003 , 18, 559-68	6.1	53
102	Helicobacter pylori treatment: a practical approach. <i>American Journal of Gastroenterology</i> , 2006 , 101, 497-9	0.7	52
101	A prospective trial of self-expanding metal stents in the palliation of malignant esophageal strictures near the upper esophageal sphincter. <i>Gastrointestinal Endoscopy</i> , 1997 , 45, 300-3	5.2	51
100	Short- and long-term outcome of esophageal perforation. <i>Gastrointestinal Endoscopy</i> , 1995 , 41, 130-4	5.2	50
99	Cost of detecting malignant lesions by endoscopy in 2741 primary care dyspeptic patients without alarm symptoms. <i>Clinical Gastroenterology and Hepatology</i> , 2009 , 7, 756-61	6.9	45
98	Sequential Therapy for Helicobacter Pylori Eradication: The Time is Now!. <i>Therapeutic Advances in Gastroenterology</i> , 2009 , 2, 317-22	4.7	44
97	Effect of push enteroscopy on transfusion requirements and quality of life in patients with unexplained gastrointestinal bleeding. <i>American Journal of Gastroenterology</i> , 1997 , 92, 425-8	0.7	44
96	Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 507-10	6.9	43
95	The cost-effectiveness of diagnostic testing strategies for. <i>American Journal of Gastroenterology</i> , 2000 , 95, 1691-1698	0.7	40
94	Prescribing proton pump inhibitors: is it time to pause and rethink?. <i>Drugs</i> , 2012 , 72, 437-45	12.1	39
93	Randomized-controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: does a 1-week trial of acid suppression predict symptom response?. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 26, 673-82	6.1	39
92	Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group. <i>Archives of Internal Medicine</i> , 1998 , 158, 852-60		39
91	Treatment for H. pylori infection: new challenges with antimicrobial resistance. <i>Journal of Clinical Gastroenterology</i> , 2013 , 47, 383-8	3	37
90	Human Tissue Responses to Metal Stents. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 1999 , 9, 359-365	3.3	36
89	Proton pump inhibitors and the time trends for esophageal dilation. <i>American Journal of Gastroenterology</i> , 2004 , 99, 797-800	0.7	34

88	Ten-day triple therapy with ranitidine bismuth citrate, amoxicillin, and clarithromycin in eradicating <i>Helicobacter pylori</i> . <i>American Journal of Gastroenterology</i> , 1999 , 94, 1197-9	0.7	31
87	Cost-effectiveness of treatment regimens for the eradication of <i>Helicobacter pylori</i> in duodenal ulcer. <i>American Journal of Gastroenterology</i> , 1996 , 91, 239-45	0.7	31
86	Symptomatic gastro-oesophageal reflux, arousals and sleep quality in patients undergoing polysomnography for possible obstructive sleep apnoea. <i>Alimentary Pharmacology and Therapeutics</i> , 2004 , 20, 1153-9	6.1	30
85	Review article: the role of surgery in gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 25, 1365-72	6.1	29
84	Funding source and conflict of interest disclosures by authors and editors in gastroenterology specialty journals. <i>American Journal of Gastroenterology</i> , 2007 , 102, 1146-50	0.7	28
83	Patterns of gastritis and the effect of eradicating <i>Helicobacter pylori</i> on gastro-oesophageal reflux disease in Western patients with non-ulcer dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 24, 55-63	6.1	28
82	Epithelial Thickness is a Marker of Gastroesophageal Reflux Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1544-1551.e1	6.9	28
81	Symptom burden and consulting behavior in patients with overlapping functional disorders in the US population. <i>United European Gastroenterology Journal</i> , 2016 , 4, 413-22	5.3	26
80	Acid inhibition and infections outside the gastrointestinal tract. <i>American Journal of Gastroenterology</i> , 2009 , 104 Suppl 2, S17-20	0.7	24
79	Clinical trial design in adult reflux disease: a methodological workshop. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 28, 107-26	6.1	24
78	Rifabutin Triple Therapy is Effective in Patients With Multidrug-resistant Strains of <i>Helicobacter pylori</i> . <i>Journal of Clinical Gastroenterology</i> , 2018 , 52, 137-140	3	22
77	Mortality and complications following surgery for diverticulitis: Systematic review and meta-analysis. <i>United European Gastroenterology Journal</i> , 2016 , 4, 706-713	5.3	22
76	Sequential therapy for <i>Helicobacter pylori</i> : time to consider making the switch?. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 300, 1346-7	27.4	22
75	One-week acid suppression trial in uninvestigated dyspepsia patients with epigastric pain or burning to predict response to 8 weeks treatment with esomeprazole: a randomized, placebo-controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 26, 665-72	6.1	22
74	Effect of <i>Helicobacter pylori</i> eradication on development of dyspeptic and reflux disease in healthy asymptomatic subjects. <i>Gut</i> , 2003 , 52, 1543-7	19.2	21
73	IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial. <i>Gastroenterology</i> , 2020 , 158, 2093-2103	13.3	20
72	Endoscopy in GERD: Boondoggle, Diagnostic Test, or Risk Management Tool?. <i>American Journal of Gastroenterology</i> , 2008 , 103, 276-8	0.7	18
71	Measurement of lesions by endoscopy: an overview. <i>Endoscopy</i> , 1995 , 27, 694-7	3.4	18

70	An international primary care survey of GERD terminology and guidelines. <i>Digestive Diseases</i> , 2008 , 26, 231-6	3.2	17
69	Glucagon Is a Safe and Inexpensive Initial Strategy in Esophageal Food Bolus Impaction. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 841-5	4	15
68	Validation of the reflux symptom questionnaire electronic diary in partial responders to proton pump inhibitor therapy. <i>Clinical and Translational Gastroenterology</i> , 2012 , 3, e7	4.2	15
67	Are there geographical and regional differences in Helicobacter pylori eradication?. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2003 , 17 Suppl B, 30B-32B		15
66	Unrecognized GERD symptoms are associated with excessive daytime sleepiness in patients undergoing sleep studies. <i>Digestive Diseases and Sciences</i> , 2007 , 52, 2873-6	4	14
65	Can famotidine and omeprazole be combined on a once-daily basis?. <i>Scandinavian Journal of Gastroenterology</i> , 2007 , 42, 689-94	2.4	14
64	Comprehension and awareness of symptoms in women with dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2005 , 22, 1147-55	6.1	14
63	Human tissue responses to metal stents. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 1999 , 9, 359-65	3.3	14
62	Approach to gastroesophageal reflux disease in primary care: Putting the Montreal definition into practice. <i>Canadian Family Physician</i> , 2008 , 54, 701-5	0.9	13
61	Sleep disturbance due to heartburn and regurgitation is common in patients with functional dyspepsia. <i>United European Gastroenterology Journal</i> , 2016 , 4, 191-8	5.3	13
60	Metal stents for malignant esophageal obstruction. <i>American Journal of Gastroenterology</i> , 1996 , 91, 2471-6	0.6	13
59	Pneumatic dilation in achalasia. <i>Endoscopy</i> , 2003 , 35, 526-30	3.4	12
58	Review article: esomeprazole, 40 mg once daily, compared with lansoprazole, 30 mg once daily, in healing and symptom resolution of erosive oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2003 , 17 Suppl 1, 21-3	6.1	12
57	Helicobacter pylori eradication: equivalence trials and the optimal duration of therapy. <i>American Journal of Gastroenterology</i> , 2005 , 100, 1702-3	0.7	12
56	Patient-centred endpoints in economic evaluations of gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2002 , 16, 1469-80	6.1	11
55	Diagnosis of gastro-oesophageal reflux disease is enhanced by adding oesophageal histology and excluding epigastric pain. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 1350-1357	6.1	10
54	Dietary Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols (FODMAPs) and Gastrointestinal Disease. <i>Nutrition in Clinical Practice</i> , 2018 , 33, 468-475	3.6	10
53	The initial diagnosis of GERD. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2013 , 27, 365-71	2.5	10

52	Funding source and conflict of interest disclosures by authors and editors in gastroenterology specialty journals revisited. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 690-5	6.1	10
51	The effect of over-the-counter ranitidine 75 mg on night-time heartburn in patients with erosive oesophagitis on daily proton pump inhibitor maintenance therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 23, 649-53	6.1	10
50	The frontiers of reflux disease. <i>Digestive Diseases and Sciences</i> , 2006 , 51, 1887-95	4	10
49	Review article: cost-effectiveness of different GERD management strategies. <i>Alimentary Pharmacology and Therapeutics</i> , 2002 , 16 Suppl 4, 79-82	6.1	10
48	Review article: endoscopic treatments for gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003 , 17, 1427-34	6.1	10
47	The Italian validation of the Montreal Global definition and classification of gastroesophageal reflux disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2009 , 21, 394-408	2.2	9
46	Duplicate breath testing to confirm eradication of <i>Helicobacter pylori</i> : incremental benefit and cost in 419 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 28, 1304-8	6.1	9
45	Review article: test and treat or treat and test in reflux disease?. <i>Alimentary Pharmacology and Therapeutics</i> , 2003 , 17 Suppl 2, 57-9	6.1	9
44	Non-invasive tests for the diagnosis of <i>H. pylori</i> infection. <i>Reviews in Gastroenterological Disorders</i> , 2004 , 4, 1-6		8
43	Salivary pepsin to diagnose GORD?. <i>Gut</i> , 2015 , 64, 361-2	19.2	7
42	Gastroösophageale Refluxkrankheit. <i>Monatsschrift Fur Kinderheilkunde</i> , 2010 , 158, 164-176	0.2	7
41	Expandable metal stents: principles and tissue responses. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2011 , 21, 351-7, vii	3.3	6
40	Prevalence of gastro-oesophageal reflux disease with upper gastrointestinal symptoms without heartburn and regurgitation. <i>United European Gastroenterology Journal</i> , 2014 , 2, 173-8	5.3	5
39	Development and validation of a patient-reported outcome instrument in partial responders to proton pump inhibitors. <i>Scandinavian Journal of Gastroenterology</i> , 2013 , 48, 1018-26	2.4	5
38	Proton pump inhibitors for dyspepsia. <i>Digestive Diseases</i> , 2008 , 26, 215-7	3.2	5
37	Is the stool test out of breath?. <i>Digestive and Liver Disease</i> , 2000 , 32, 291-3	3.3	5
36	<i>Helicobacter pylori</i> treatment: is sequential or quadruple therapy the answer?. <i>Reviews in Gastroenterological Disorders</i> , 2008 , 8, 77-82		5
35	Body mass index and gastroesophageal reflux disease: implications of the obesity epidemic. <i>Digestive Diseases and Sciences</i> , 2008 , 53, 2291-2	4	4

34	Pretreatment endoscopy--pro & contra: is endoscopy needed before treatment in all patients with gastroesophageal reflux disease?. <i>Endoscopy</i> , 2006 , 38, 276-8	3.4	4
33	How to test for Helicobacter pylori in 2005. <i>Cleveland Clinic Journal of Medicine</i> , 2005 , 72 Suppl 2, S8-13; discussion S14-21	2.8	4
32	Multitarget stool DNA testing for the prevention of colon cancer: outcomes in a large integrated healthcare system. <i>Gastrointestinal Endoscopy</i> , 2020 , 92, 334-341	5.2	4
31	Gender differences in symptoms in partial responders to proton pump inhibitors for gastro-oesophageal reflux disease. <i>United European Gastroenterology Journal</i> , 2015 , 3, 443-52	5.3	3
30	Symptom profile in partial responders to a proton pump inhibitor compared with treatment-naïve patients with gastroesophageal reflux disease: a post hoc analysis of two study populations. <i>BMC Gastroenterology</i> , 2014 , 14, 177	3	3
29	Nonulcer dyspepsia. <i>Current Gastroenterology Reports</i> , 2002 , 4, 455-8	5	3
28	Toward a simplified strategy for managing dyspepsia. <i>Postgraduate Medicine</i> , 2005 , 117, 13-6	3.7	3
27	Microbiome: In Search of Mechanistic Information and Relevance. <i>American Journal of Gastroenterology</i> , 2019 , 114, 1014-1016	0.7	3
26	Colorectal cancer in 18- to 49-year-olds: rising rates, presentation, and outcome in a large integrated health system. <i>Gastrointestinal Endoscopy</i> , 2021 , 94, 618-626	5.2	3
25	Gastroesophageal reflux disease and Helicobacter pylori infection. <i>Reviews in Gastroenterological Disorders</i> , 2003 , 3, 1-7		3
24	Aerobic exercise and caloric reduction should be the key lifestyle modifications in obese patients with GERD. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 1133-4; discussion 1134-5	6.1	2
23	A BALANCING VIEW: Endoscopy in dyspepsia: a tale of two cities. <i>American Journal of Gastroenterology</i> , 2007 , 102, 476-7	0.7	2
22	Long-term strategies: a medico-economic perspective. <i>European Journal of Gastroenterology and Hepatology</i> , 2004 , 16, 853-6	2.2	2
21	Esophageal cancer. <i>Current Opinion in Gastroenterology</i> , 2002 , 18, 486-9	3	2
20	Novel methods of using proton-pump inhibitors. <i>Gastroenterology Clinics of North America</i> , 2002 , 31, S85-8	4.4	2
19	Endoscopic Measurement of Lesion Size. <i>Digestive Endoscopy</i> , 1999 , 11, 193-197	3.7	2
18	The prevention of gastropathy and upper abdominal symptoms caused by nonsteroidal anti-inflammatory drugs. <i>Reviews in Gastroenterological Disorders</i> , 2006 , 6, 221-6		2
17	New pharmacological agents for the treatment of gastroesophageal reflux disease. <i>Reviews in Gastroenterological Disorders</i> , 2008 , 8, 117-22		2

16	Helicobacter pylori. Can Helicobacter pylori infection prevent allergic asthma?. <i>Reviews in Gastroenterological Disorders</i> , 2009 , 9, E66-7		2
15	Antimicrobial resistance and eradication strategies for Helicobacter pylori. <i>Reviews in Gastroenterological Disorders</i> , 2009 , 9, E78-83		2
14	Rationale for a Helicobacter pylori Test and Treatment Strategy in Gastroesophageal Reflux Disease. <i>Gastroenterology Clinics of North America</i> , 2015 , 44, 661-6	4.4	1
13	An overview of the success and failure of surgical therapy: standards against which the outcome of endoscopic therapy is measured. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2003 , 13, 69-73, viii	3.3	1
12	Treatment of H. pylori infection: the reality. <i>Yale Journal of Biology and Medicine</i> , 1998 , 71, 119-24	2.4	1
11	Epigastric pain in dyspepsia and reflux disease. <i>Reviews in Gastroenterological Disorders</i> , 2003 , 3 Suppl 4, S16-21		1
10	Increasing compliance with long-term therapy: avoiding complications and adverse events. <i>Reviews in Gastroenterological Disorders</i> , 2005 , 5 Suppl 2, S12-7		1
9	New developments in the treatment of Helicobacter pylori: is sequential therapy the answer?. <i>Reviews in Gastroenterological Disorders</i> , 2008 , 8, 217-8		1
8	Commentary: tegaserod and IBS, two decades on. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 200-201	6.1	
7	Commentary: balloon distension of the oesophagus - not ready for primetime. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 36, 202-3	6.1	
6	Response to Tack and Carbone. <i>American Journal of Gastroenterology</i> , 2013 , 108, 1810	0.7	
5	Meta-analysis: the efficacy of proton pump inhibitors for laryngeal symptoms attributed to gastro-oesophageal reflux disease. <i>Clinical Otolaryngology</i> , 2008 , 33, 114-114	1.8	
4	Helicobacter Pylori and Non-ulcer Dyspepsia. <i>Current Treatment Options in Gastroenterology</i> , 2000 , 3, 341-345	3.5	
3	Endoscopic imaging technology. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 1994 , 4, 463-73	3.3	
2	Dyspepsia, non-ulcer dyspepsia, and Helicobacter pylori. <i>Reviews in Gastroenterological Disorders</i> , 2001 , 1, 139-46		
1	The potential dangers of test-and-treat strategies directed at H. pylori. <i>Reviews in Gastroenterological Disorders</i> , 2004 , 4, 94-5		